Sodium-glucose cotransporter 2 inhibitors and renin-angiotensin-aldosterone system, possible cellular interactions and benefits.

Autor: Forouzanmehr B; Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran., Hedayati AH; Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran., Gholami E; Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran., Hemmati MA; Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran., Maleki M; Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Butler AE; Research Department, Royal College of Surgeons in Ireland Bahrain, Adliya 15503, Bahrain., Jamialahmadi T; Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran., Kesharwani P; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India. Electronic address: prashantdops@gmail.com., Yaribeygi H; Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran. Electronic address: habib.yari@yahoo.com., Sahebkar A; Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Applied Biomedical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: amir_saheb2000@yahoo.com.
Jazyk: angličtina
Zdroj: Cellular signalling [Cell Signal] 2024 Oct; Vol. 122, pp. 111335. Date of Electronic Publication: 2024 Aug 06.
DOI: 10.1016/j.cellsig.2024.111335
Abstrakt: Sodium glucose cotransporter 2 inhibitors (SGLT2is) are a newly developed class of anti-diabetics which exert potent hypoglycemic effects in the diabetic milieu. However, the evidence suggests that they also have extra-glycemic effects. The renin-angiotensin-aldosterone system (RAAS) is a hormonal system widely distributed in the body that is important for water and electrolyte homeostasis as well as renal and cardiovascular function. Therefore, modulating RAAS activity is a main goal in patients, notably diabetic patients, which are at higher risk of complications involving these organ systems. Some studies have suggested that SGLT2is have modulatory effects on RAAS activity in addition to their hypoglycemic effects and, thus, these drugs can be considered as promising therapeutic agents for renal and cardiovascular disorders. However, the exact molecular interactions between SGLT2 inhibition and RAAS activity are not clearly understood. Therefore, in the current study we surveyed the literature for possible molecular mechanisms by which SGLT2is modulate RAAS activity.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: